PND26 Cost-effectiveness analysis of prophylaxis versus on-demand supply of factor ix in patients diagnosed with severe hemophilia B in Colombia  by Ordoñez Molina, J.E. & Orozco Giraldo, J.J.
A104 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  
  
 
neuroleptic/serotonin syndrome, impulse control disorder, somnolence, sleep 
attacks, hallucinations, psychoses) and for all AEs combined. Index dates were 
assigned as first AE diagnosis for cases and first anti-PD prescription claim for 
controls. Patients were enrolled pre-index for ≥6 months and post-index for ≥12 
months. All-cause costs were aggregated over 12 months post-index. Costs  
(2012 $) were adjusted using GLM models with covariates for demographics and 
pre-index comorbidities. RESULTS: A total of 71,883 patients met the inclusion 
criteria, 45,719 with ≥1 AE (mean[SD] age: 74.9[11.0] years, 55% male) and 26,164 
with no AEs (mean[SD] age: 75.0[10.9] years, 59% male). Among patients with ≥1 
AE, mean total all-cause costs per patient were substantially higher as compared 
with controls ($23,568 vs. $13,633; p<0.001), with the difference driven roughly 
equally by incremental inpatient and outpatient costs of $4,398 and $5,031, 
respectively (both p<0.001). For all AEs individually, patients experiencing the AE 
had substantially higher mean all-cause costs, with the largest differences for 
orthostatic hypotension ($30,551 vs. $17,635), hallucinations ($30,822 vs. $17,843), 
and nausea ($32,865 vs. $16,456) (all p<0.001). CONCLUSIONS: PD patients 
experiencing AEs incur substantially higher costs as compared with patients 
without AEs. These data may be useful in evaluating the cost-effectiveness of 
new PD therapies with more favorable AE profiles.  
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OBJECTIVES: The current study is a longitudinal analysis of costs in dementia 
from a societal perspective. The data were collected as part of the AgeCoDe 
study. The aim of this study is to analyse excess costs of dementia over time 
while taking into account the initial degree of severity and to investigate 
potential predictors of costs over time. METHODS: Health care resource use and 
costs were assessed retrospectively using a questionnaire in four waves at 6-
month intervals in a sample of dementia patients (N=175) and a non-demented 
control sample (N=173) matched for age and gender. Sociodemographic data, 
dementia severity and comorbidity at baseline, cognitive impairment and 
impairment in activities of daily living (ADL) were also recorded. Statistical 
analyses were performed by means of the χ2 test or Fisher’s exact test, two-tailed 
t-tests and linear mixed regression models with random intercepts for 
individuals. We used bootstrapped standard errors (based on 4000 replications) 
in regression analyses to account for the skewness of the cost data. RESULTS: 
For patients with mild dementia, costs increased by approximately €900 (US-
$1250) per six months, while they decreased by €2700 (US-$3750) in patients with 
severe dementia. ADL impairment significantly predicted total costs in dementia 
patients. Higher age was associated with higher formal care costs, but lower 
informal care costs. CONCLUSIONS: In patients with mild dementia, costs rose 
over time, while they decrease in severely demented patients. Transition into a 
nursing home is likely in severely demented patients, which may reduce total 
costs from a societal perspective, owing to the fact that a high amount of 
informal care required by severely demented patients prior to transition into a 
nursing home may cause higher costs than inpatient nursing care.  
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OBJECTIVES: Patients with multiple sclerosis (MS) who have relapses are treated 
with corticosteroids and sometimes admitted to the hospital. The objective of 
this study is to examine changes in corticosteroid utilization, MS-related 
inpatient hospitalization, and related costs in MS patients before and after 
initiating natalizumab treatment in a real-world setting. METHODS: A 
retrospective administrative claims analysis was conducted using a large US 
commercial and Medicare supplemental database. The study population 
included adult patients diagnosed with MS who initiated natalizumab treatment 
between January 1, 2007, and December 31, 2010 (index), had not received any 
MS disease-modifying therapy for 12 months prior to index, and had ≥24 months 
of continuous data (12 months before and after index). Patient characteristics at 
index and corticosteroid use, MS-related inpatient hospitalizations, and related 
costs 12 months before (pretreatment) and 12 months after (posttreatment) 
natalizumab treatment initiation were analyzed and described using paired 
statistical tests. RESULTS: Data were from 535 patients: 70.1% female, mean age 
45.8 (standard deviation 11.2) years. Compared with the previous 12 months, the 
proportions of patients with oral and IV corticosteroid use significantly 
decreased by 10.3% (28.6% pretreatment vs 18.3% posttreatment; P<0.001) and 
16.7% (34.8% pretreatment vs. 18.1% posttreatment; P<0.001), respectively, after 
12 months from natalizumab initiation. Mean expenditure per patient of oral and 
IV corticosteroid prescriptions decreased by 57.1% (P=0.002) and 54.7% (P=0.007), 
respectively. A significant reduction was observed in the proportion of patients 
with MS-related inpatient hospitalizations (7.3% pretreatment vs. 3.0% 
posttreatment; P=0.001), as well as in MS-related inpatient hospital expenditures 
among patients with an inpatient admission (median cost per patient: $12,078 
pretreatment vs $9,289 posttreatment; P=0.001). CONCLUSIONS: Indicators of MS 
relapses, MS-related inpatient hospitalizations and corticosteroid use, were 
significantly reduced in MS patients 12 months after initiating natalizumab 
treatment in a real-world setting both in terms of costs and health resource 
utilization.  
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OBJECTIVES: Hemophilia is a genetic disease in which there is a deficiency in the 
level of activity of the coagulation factors. Hemophilia A (factor VIII deficiency) 
has a prevalence of 3.96 per 100,000 in Colombia (96.7% male); Severe hemophilia 
is defined as a blood clotting factor level ≤1%. This analysis is aimed to estimate 
the cost-effectiveness of prophylactic treatment of severe hemophilia A, 
compared to demand treatment in Colombia. METHODS: A decision tree model 
was developed using a time horizon of life expectancy. A societal perspective 
was adopted; annual discount rate of 3% was applied to costs and effectiveness 
measures. Prophylactic treatment with recombinant factor VIII (25 UI/kg 3 times 
per week) was compared to on demand treatment (50 UI/kg TID for 7 days for 
each bleeding episode). A cohort of 1,000 patients (0-14 years) with an average 
weight of 40kg and inhibitors present was simulated. Effectiveness and 
probabilities of adverse events were taken from the literature. Costs (direct and 
indirect) were taken from local tariff manuals (SOAT and SISMED). Effectiveness 
measures were number of cases avoided of bleeding and joint damage. All data 
were validated with a clinical expert. Univariate sensitivity analysis was done. 
Costs are presented in 2012 US$. RESULTS: Over the time horizon evaluated, 
prophylactic treatment avoids 823 cases of bleeding and 292 of joint damage. 
Total expected costs with prophylactic treatment were US$2.6M compared to on 
demand treatment US$1.7M. The incremental cost effectiveness ratio (ICER) for 
prophylactic treatment was US$1,079/avoid bleed, US$3,042/avoided joint 
damage. Sensitivity analysis showed the robustness of the model. 
CONCLUSIONS: From the social perspective, prophylactic treatment of severe 
hemophilia A, with recombinant factor VIII would be a highly cost-effectiveness 
intervention with strong health benefits in number of cases of bleeding and joint 
damage avoided (cost-effectiveness threshold: 1 Colombian GDP per capita = 
US$7,235).  
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OBJECTIVES: Few studies regarding the head-to-head cost-effectiveness analysis 
of medications treating for Alzheimer’s Disease have been conducted in Asia. 
The goal of this study is to perform a comparative assessment of donepezil and 
rivastigimine on the costs and efficacy of mild to moderate AD patients. 
METHODS: A four-state Markov model was built to simulate the disease 
progression of the mild to moderate AD patients’ life span (from sixty five years 
of age to death). Transition probabilities between states and the cost of medical 
treatments at different stages derived from the local data in Taiwan. Analyses 
were run to evaluate outcomes for patients with mild AD from societal 
perspective. While all cost outcome have been discounted at 3% per annum. 
RESULTS: The result of the Markov cohort simulation shows that for the life 
expectancy in the long-term, rivastigmine treatment is the dominant strategy as 
it is more effective and economical than the alternatives. Specifically, treating 
patients with rivastigmine, compared with no treatment, yielded a 0.34 quality-
adjusted life years (QALYs) increase per patient over the life time. Furthermore, 
the average cost savings per patient favored rivastigmine by resulting in 
US$10,503 from the societal perspective (2012 USD). For the donepezil versus 
rivastigmine base-case comparison, patients on donepezil gained 0.64 QALYs. 
Cost savings for the donepezil group were US$50,312 from the societal 
perspective. CONCLUSIONS: It is concluded that donepezil and rivastigmine are 
the two medical treatments that might be a cost saving strategy for mild or 
moderate AD patients in Taiwan from the societal perspective.  
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OBJECTIVES: Hemophilia is a recessive genetic disease that does not allow 
adequate blood clotting; this is characterized by a defect in coagulation factors, 
needed for this function. Hemophilia B (factor IX deficiency) has a prevalence of 
0.81 per 100,000 in Colombia (96% male). Severe hemophilia is defined as a blood 
clotting factor level ≤1%. This analysis is aimed to estimate the cost-
effectiveness of prophylactic treatment of severe hemophilia B, compared to on 
demand treatment in Colombia. METHODS: A decision tree model was 
developed using a time horizon of life expectancy. A societal perspective was 
adopted, and an annual discount rate of 3% was applied to costs and 
effectiveness measures. Prophylactic treatment with recombinant factor IX (25 
IU/kg 2 times per week) was compared to on demand treatment (50 UI/kg TID for 
8.5 days for each bleeding episode). A cohort of 1000 patients (age 15 - 62), with 
an average weight of 60kg was simulated: estimates of effectiveness and 
probabilities of adverse events were taken from a literature. Costs (direct and 
indirect) were taken from local tariff manuals (SOAT and SISMED). Costs are 
presented in 2012 US$. Effectiveness measures were number of cases avoided of 
bleeding and joint damage. All data were validated with a clinical expert. 
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Univariate sensitivity analysis was done. RESULTS: Over the time horizon 
evaluated, prophylactic treatment avoids 681 cases of bleeding and 246 of joint 
damage. Total expected costs with prophylactic treatment were US$3.86M 
compared to on demand treatment US$2.09M. The incremental cost 
effectiveness ratio (ICER) for prophylactic treatment was US$2592/avoided 
bleeding and US$7172/avoided joint damage (cost-effectiveness threshold: 1 
Colombian GDP per capita = US$7235). Sensitivity analyses showed the 
robustness of the model. CONCLUSIONS: Prophylactic treatment of severe 
hemophilia B, with recombinant factor IX would be a highly cost-effective 
intervention from the social perspective.  
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OBJECTIVES: Chronic migraine produces significant societal costs and reductions 
in quality of life. OnabotulinumtoxinA is licensed in Canada for the prophylaxis 
of headaches in adults with chronic migraine. We developed a model to estimate 
the cost-effectiveness of onabotulinumtoxinA for patients with chronic migraine 
who are intolerant or refractory to two or more oral prophylaxis agents. 
METHODS: A state transition model with a three-year time horizon was 
developed to estimate the incremental impact of onabotulinumtoxinA relative to 
placebo in units of quality adjusted life years (QALYS) for adults with chronic 
migraine in Canada. Each treatment cohort was divided into health states 
defined by the number of headache days experienced per month. A societal 
perspective was taken, including cost of treatment, acute health care resource 
use, absenteeism, and presenteeism. Pooled data from the subgroup of patients 
who had previously tried two or more prophylactics in the Phase III clinical trial 
program were used to estimate the baseline health state distributions and 
transition probabilities. Quality of life and health care resource utilization were 
estimated from a large international observational study of migraine patients. 
RESULTS: Treatment with onabotulinumtoxinA produced an incremental benefit 
of 0.151 QALYs over 3 years at an incremental cost of $974 compared to placebo, 
thus resulting in an Incremental Cost Effectiveness Ratio (ICER) of $6,450/QALY. 
Results were most sensitive to hourly wage, mean lost work hours, and mean 
number of hospitalizations in the three highest headache days per month health 
states. OnabotulinumtoxinA remains cost-effective when excluding lost 
productivity costs, with an ICER of $24,504/QALY. CONCLUSIONS: In this study, 
onabotulinumtoxinA was shown to be a cost-effective treatment option and may 
be considered good value for money from a Canadian societal perspective for the 
prophylaxis of headaches in adults with chronic migraine who fail or are 
intolerant to other treatment options.  
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OBJECTIVES: Fibromyalgia is a disorder often characterized by chronic 
musculoskeletal pain over multiple regions of the body not explained by 
anatomical injury. Pregabalin is the only approved medication for fibromyalgia 
in Taiwan. This study aims to estimate the cost-effectiveness of pregabalin for 
treatment of severe fibromyalgia in Taiwan. METHODS: A decision-analytic 
model was constructed for projecting the effects and costs of pharmaceutical 
treatment of fibromyalgia sufferers in Taiwan. Treatment comparators and 
utilization patterns were provided through local physician questionnaires and a 
national key opinion leader advisory board (rheumatologist, pain specialists and 
neurologist). Costs were collected from local published data. Response (30% 
improvement over baseline in pain score and patient global impression) and 
non-response of a single patient were modeled to pregabalin 300mg or 450mg 
versus placebo and alternative medications used in practice as suggested by the 
advisory board (amitriptyline 25mg, duloxetine 60/120mg, tramadol 200mg, or 
gabapentin 1800mg) for 12 weeks, followed by a three-year Markov model 
depicting maintained response, lost response, or stopped treatment. Transition 
probabilities were retrieved from published randomized trials. Effectiveness was 
quality-adjusted life years (QALYs). Costs and QALYs were annually discounted 
at 3%. Annual costs were reported in 2013 US$. RESULTS: The base case patient 
was a 42 year old woman. Compared pregabalin 300mg and 450mg with placebo, 
the incremental cost-effectiveness ratios (ICERs) were $33,369/QALY and 
$49,040/QALY. The ICERs for pregabalin 300mg versus duloxetine 60mg/120mg, 
tramadol, or gabapentin were $33,009/QALY, $3,377/QALY, $189,956/QALY, and 
$36,318/QALY, respectively. The ICERs for pregabalin 450mg versus duloxetine 
60mg, duloxetine 120mg, tramadol, or gabapentin were $63,970/QALY, 
$39,697/QALY, $237,612/QALY, and $66,755/QALY, respectively. Both pregabalin 
300mg and 450mg had higher cost and lower QALYs than amitriptyline. The 
results are robust under probabilistic sensitivity analysis. CONCLUSIONS: 
Depending on a budgetary authority’s willingness to pay, pregabalin may be 
cost-effective against placebo and alternative treatments.  
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OBJECTIVES: Urinary incontinence (UI) secondary to a neurogenic pathology, 
including spinal cord injury (SCI) and Multiple Sclerosis (MS), is termed 
neurogenic detrusor overactivity (NDO). Patients with NDO experience a 
decrease in quality of life (QoL) and are at risk for upper urinary tract damage. 
We sought to investigate the clinical and economic impact of 
onabotulinumtoxinA treatment for UI due to NDO from the US payer perspective. 
METHODS: We developed a Markov state transition model to estimate outcomes 
and costs for anticholinergic refractory NDO patients who received 
onabotulinumtoxinA or best supportive care (BSC). Non-responding patients 
(<50% reduction in UI episodes at 6 weeks) were eligible to receive invasive 
procedures (i.e. augmentation cystoplasty or sacral neuromodulation). Patients 
could transition through six health states defined by response to initial 
treatment, invasive procedures, and death. Time in each health state was 
adjusted for patient QoL and summed to estimate quality-adjusted life years 
(QALY). We included direct medical costs related to medications and invasive 
treatments, physician visits, and catheterization. Outcomes and costs were 
compared using the incremental cost-effectiveness ratio. The time horizon of the 
model was 3 years and results were discounted at 3%. RESULTS: 
OnabotulinumtoxinA increased QALYs by 0.059 and costs by $1,466 compared to 
best supportive care, yielding an estimated ICER of $24,720/QALY. 
OnabotulinumtoxinA also decreased mean incontinence episodes per person-
year by 400, resulting in a cost of $4 per incontinence episode avoided. Model 
results were most sensitive to the probability of treatment response. The 
probabilistic sensitivity analysis indicated that at a willingness to pay of 
$50,000/QALY, onabotulinumtoxinA has a 97% probability of being cost-effective. 
In subgroup analyses of each etiology, onabotulinumtoxinA yielded an ICER of 
$32,268/QALY in MS and $2,182 in SCI. CONCLUSIONS: OnabotulinumtoxinA 
appears to be a cost-effective intervention for UI due to NDO when compared to 
best supportive care.  
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OBJECTIVES: Examine the number of hospitalizations, emergency room  
(ER) visits, fractures, and falls among patients diagnosed with Parkinson Disease 
(PD) initiating therapy with either Selegiline (SEL) or Rasagiline (RAS). METHODS: 
This study utilized data from the Truvan Health Analytics MarketScan Claims 
and Encounters Database from 1/1/2006 through 3/31/2011. Eligible patients  
filled a prescription for SEL or RAS, with first such date identified as index date, 
were diagnosed with PD (ICD-9-CM 332 or 332.0) in the 2 years post the index 
date (i.e., the post-period), and were continuously insured from 6 months prior 
(i.e., the pre-period) through the end of the post-period. Logistic regressions  
were utilized to estimate adjusted odds ratios of hospitalizations and ER visits 
(both total and PD-related) as well as odds of fractures and falls,  
while controlling for socio-demographic and clinical characteristics. The apriori 
specified level of significance was 5%. RESULTS: There were 3,864 individuals  
in the analyses (1,085 SEL; 2,779 RAS). On average, RAS patients were slightly 
younger (56.3 v 56.8 years; P=0.0320), had a significantly higher copayment 
associated with initial prescription ($44.72 v $21.36; P<0.0001) and  
were significantly more likely to have a comorbid diagnosis of high cholesterol 
(18.10% v 14.01%; P=0.0023). After controlling for patient characteristics, general 
health, disability status, comorbid diagnoses, and index prescription 
characteristics, RAS was associated with significantly lower likelihood of  
all-cause hospitalizations in the post-period (OR=0.821; 95% CI= 0.682 – 0.988), 
all-cause ER visits (OR=0.791; CI =0.677 – 0.926), PD-related ER visits (OR=0.793; 
CI=0.643 – 0.979), and falls (OR=0.552; CI=0.335 – 0.909) compared to  
patients initiating with SEL. There was not a significant difference between the 
cohorts in the odds of fracture or the odds of a PD-related hospitalization. 
CONCLUSIONS: Among patients with PD, initiation with RAS compared to SEL is 
associated with significantly fewer all-cause hospitalizations and ER visits and 
fewer falls.  
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OBJECTIVES: Patient perceptions regarding disease modifying therapies (DMT) in 
multiple sclerosis (MS) are limited to a few studies. Although DMT use has been 
shown to be beneficial in terms of preventing relapses and disability progression, 
many MS patients do not initiate therapy for unclear reasons. The objectives 
were to quantify and evaluate perceptions of MS patients not currently being 
treated with DMTs towards MS as a disease state and DMT initiation, in  
a regional health plan using the Multiple Sclerosis Medication Questionnaire 
